Switch to Europe/Worldwide website Switch to German website Switch to French website Switch to OriGene Technologies, Inc. (North America)
Home » Suppliers

Suppliers

(reset)
  1. Quick-Filters:
  2. Cited (10)

10 Item(s)

per page

Primary Antibodies

Catalog No. Host Iso. Clone Pres. React. Applications  

BETVIA allergen Bet v1 antibody
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG2 H.G27E9B1 Purified Pollen E, IP
0.1 mg / $600.00
  Dendritics SAS

BETVIA antibody
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG3 H.G26F6B2.06 Purified Pollen E
0.1 mg / $600.00
  Dendritics SAS

BETVIA antibody
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG4 H.G11A9F3.03 Purified Pollen E
0.1 mg / $600.00
  Dendritics SAS

BETVIA antibody
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG4 H.G28C10.01 Purified Pollen E
0.1 mg / $600.00
  Dendritics SAS

BETVIA antibody
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG1 H.G5F2A4.09 Purified Pollen E, WB
0.1 mg / $600.00
  Dendritics SAS

BETVIA antibody
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Human IgG2 H.G3A3C2.04 Purified Pollen E
0.1 mg / $600.00
  Dendritics SAS

BETVIA antibody
Enriched basophils from birch pollen were incubated with concentrations of nBetV1 inducing from 50 to 100% of the maximal histamine release in the presence or the absence of the mentioned HumAbs. The histamine releasewas expressed as a percentage of maximal histamine release. The mean and SD of three measurements are presented. A, when tested indicidually, only BAB1 inhibits the Betv1-induced histamine release. The five HumAbs were individually preincubated, at concentrations ranging from 0.4 to 1.5mg/ml with nBetv1 before challenging exposure of the basophils of two allergic patients (M.M and J.C). B, BAB 1 preincubated at 1.5mg/ml with nBetv1 inhibits the histamine release from the basophils of the four patients tested (H.L, E.B, M.M, and J.C). C, the Betv1-induced histamine release inhibition is specific and dose-dependent. nBetv1 was preincubated with successive dilutions of an anti-IL1a HumAB X3A3 (starting from 1.3mg/ml), of BAB1 (starting from 1.5mg/ml) or of amixture of BAB2 to BAB5 (starting at 0.1mg/ml for each) and then exposed to the baophils from patient J.C. Mouse IgG4 H.G17E7A1 Purified Pollen E
0.1 mg / $600.00
  Dendritics SAS

Birch Pollen allergen Bet v1 antibody
Cross-reactivity with Bet v 1 homologous plant allergens Mouse IgG1 102H10.05 Purified Pollen NEUT
0.1 mg / $440.00
  Dendritics SAS
+2 additional images

Birch Pollen allergen Bet v1 antibody
mAbs binding to nitrocellulose-blotted natural (n) or recombinant birch pollen Bet v 1 Mouse IgG1 110G10.01 Purified Pollen NEUT
0.1 mg / $440.00
  Dendritics SAS
+2 additional images

Birch Pollen allergen Bet v1 antibody
Modulation of IgE (allergic patients) binding to Bet v 1 Mouse IgG1 202B8.03 Purified Pollen NEUT
0.1 mg / $440.00
  Dendritics SAS
+3 additional images

10 Item(s)

per page

Active Filters

  1. Remove This Filter Reactivity: Pollen
Clear All Filters

Available Filters

Product Type
  1. Primary Antibody (10)
Clonality
  1. Monoclonal (10)
Target
  1. BETVIA (7)
  2. Birch Pollen (3)
Property
  1. allergen Bet v1 (4)
Applications
  1. Enzyme Immunoassay (E) (7)
  2. Neutralisation (NEUT) (3)
  3. Immunoprecipitation (IP) (1)
  4. Western blot / Immunoblot (WB) (1)
Presentation
  1. Purified (10)
Host
  1. Human (6)
  2. Mouse (4)
Images
  1. 1 image (10)
  2. 3+ images (3)
Images: Applications
  1. Immunoprecipitation (IP) (1)
  2. Neutralisation (NEUT) (1)
Manufacturer
  1. Dendritics SAS (10)
Service
 
© Copyright 1998 - 2018 OriGene Technologies, Inc.
  • LinkedIn